Repligen
RGEN
Repligen (RGEN) - P/B ratio
P/B ratio as of May 2024 : 4.88
According to Repligen
's latest financial reports the company has a price-to-book ratio of 4.88.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Repligen - P/B ratio (from 2001 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | N/A | -100% |
| 2023-12-31 | 5.09 | 3.51% |
| 2022-12-31 | 4.92 | -41.2% |
| 2021-12-31 | 8.37 | 22.02% |
| 2020-12-31 | 6.86 | 50.85% |
| 2019-12-31 | 4.55 | 20.81% |
| 2018-12-31 | 3.76 | 40.83% |
| 2017-12-31 | 2.67 | -56.75% |
| 2016-12-31 | 6.18 | -18.64% |
| 2015-12-31 | 7.59 | 30.75% |
| 2014-12-31 | 5.81 | 38.56% |
| 2013-12-31 | 4.19 | 80% |
| 2012-12-31 | 2.33 | 48.22% |
| 2011-12-31 | 1.57 | -25.05% |
| 2010-12-31 | 2.10 | 11.94% |
| 2009-12-31 | 1.87 | 13.48% |
| 2008-12-31 | 1.65 | -45.55% |
| 2007-12-31 | 3.03 | -10.17% |
| 2006-12-31 | 3.37 | -27.58% |
| 2005-12-31 | 4.66 | 32.78% |
| 2004-12-31 | 3.51 | -18.64% |
| 2003-12-31 | 4.31 | 35.83% |
| 2002-12-31 | 3.17 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.82 | -62.72% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | 4.85 | -0.50% | 🇺🇸 USA |
 General Electric GE | 5.63 | 15.42% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 5.39 | 10.63% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | 1.63 | -66.64% | 🇺🇸 USA |
 Novavax NVAX | -2.67 | -154.83% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | 6.00 | 23.09% | 🇺🇸 USA |
 Bio-Techne TECH | 6.73 | 37.96% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 2.90 | -40.46% | 🇺🇸 USA |
 Charles River Laboratories
CRL | 3.12 | -36.01% | 🇺🇸 USA |